Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have earned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $11.00.
A number of analysts have recently weighed in on CNAT shares. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 1st. Finally, HC Wainwright restated a “buy” rating on shares of Conatus Pharmaceuticals in a report on Monday, November 5th.
Shares of Conatus Pharmaceuticals stock opened at $4.65 on Friday. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. Conatus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $7.95. The stock has a market cap of $143.14 million, a price-to-earnings ratio of -7.62 and a beta of 1.84.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%. The business had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $9.70 million. As a group, equities research analysts forecast that Conatus Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC boosted its holdings in shares of Conatus Pharmaceuticals by 94.6% in the 3rd quarter. Virtu Financial LLC now owns 25,860 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 12,572 shares in the last quarter. Jane Street Group LLC acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter worth approximately $142,000. MYDA Advisors LLC acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter worth approximately $154,000. Bank of America Corp DE boosted its stake in Conatus Pharmaceuticals by 75.7% in the 2nd quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock worth $602,000 after purchasing an additional 60,604 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter worth approximately $311,000. Institutional investors and hedge funds own 35.09% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
See Also: What are CEFs?
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.